United States - English - NLM (National Library of Medicine)

meijer distribution inc - fluticasone propionate (unii: o2gmz0lf5w) (fluticasone - unii:cut2w21n7u) - fluticasone propionate 50 ug - allergy symptom reliever temporarily relieves these symptoms of hay fever or other upper respiratory allergies:

United States - English - NLM (National Library of Medicine)

meijer distribution inc - fluticasone propionate (unii: o2gmz0lf5w) (fluticasone - unii:cut2w21n7u) - fluticasone propionate 50 ug - allergy symptom reliever temporarily relieves these symptoms of hay fever or other upper respiratory allergies:

Canada - English - Health Canada

apotex inc - fluticasone propionate - metered-dose aerosol - 125mcg - fluticasone propionate 125mcg

United States - English - NLM (National Library of Medicine)

selder, s.a. de c.v. - fluticasone propionate (unii: o2gmz0lf5w) (fluticasone - unii:cut2w21n7u) - fluticasone propionate 50 ug - allergy symptom reliever temporarily relieves these symptoms of hay fever or other upper respiratory allergies: - nasal congestion - runny nose - sneezing - itchy nose  - itchy, watery eyes

Canada - English - Health Canada

pharmascience inc - fluticasone propionate - metered-dose aerosol - 125mcg - fluticasone propionate 125mcg - adrenals

Ireland - English - HPRA (Health Products Regulatory Authority)

cipla europe nv - fluticasone propionate - pressurised inhalation, suspension - 125 mcg/acutuation - glucocorticoids; fluticasone

Australia - English - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - salmeterol xinafoate, quantity: 36.32 microgram/actuation (equivalent: salmeterol, qty 25 microgram/actuation); fluticasone propionate, quantity: 250 microgram/actuation - inhalation, pressurised - excipient ingredients: norflurane - for the regular treatment of asthma, where the use of a combination product is appropriate. this may include: - patients on effective maintenance doses of long-acting beta-2 agonists and inhaled corticosteroids. - patients who are symptomatic on current inhaled corticosteroid therapy.,for the symptomatic treatment of patients with severe copd (fev1 less than 50 precent predicted normal) and a history of repeated exacerbations who have significant symptoms despite regular beta-2 agonist bronchodilator therapy. fluticasone propionate/salmeterol (125 microgram/25 microgram and 250 microgram/25 microgram) is not indicated for the initiation of bronchodilator therapy in copd.

Australia - English - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - salmeterol xinafoate, quantity: 36.32 microgram/actuation (equivalent: salmeterol, qty 25 microgram/actuation); fluticasone propionate, quantity: 125 microgram/actuation - inhalation, pressurised - excipient ingredients: norflurane - for the regular treatment of asthma, where the use of a combination product is appropriate. this may include: - patients on effective maintenance doses of long-acting beta-2 agonists and inhaled corticosteroids. - patients who are symptomatic on current inhaled corticosteroid therapy.,for the symptomatic treatment of patients with severe copd (fev1 less than 50 precent predicted normal) and a history of repeated exacerbations who have significant symptoms despite regular beta-2 agonist bronchodilator therapy. fluticasone propionate/salmeterol (125 microgram/25 microgram and 250 microgram/25 microgram) is not indicated for the initiation of bronchodilator therapy in copd.

Ireland - English - HPRA (Health Products Regulatory Authority)

ltt pharma limited - fluticasone propionate - pressurised inhalation, suspension - 125 mcg/dose - glucocorticoids; fluticasone

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

de pharmaceuticals - fluticasone propionate - cutaneous cream - 500microgram/1gram